{
  "id": "5e2dbf48fbd6abf43b00001a",
  "type": "yesno",
  "question": "Has ProSavin undergone phase IV clinical trials by 2018?",
  "ideal_answer": "No, ProSavin has undergone a dose escalation, open-label, phase 1/2 trial.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24412048"
  ],
  "snippets": [
    {
      "text": "Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24412048",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We undertook a phase 1/2 open-label trial with 12-month follow-up at two study sites (France and UK) to assess the safety and efficacy of ProSavin after bilateral injection into the putamen of patients with Parkinson's disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24412048",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}